Epizyme, Inc. (EPZM): Price and Financial Metrics


Epizyme, Inc. (EPZM): $8.81

0.28 (+3.28%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add EPZM to Watchlist
Sign Up

Industry: Biotech


Ranked

of 487

in industry

EPZM POWR Grades


  • EPZM scores best on the Value dimension, with a Value rank ahead of 45.96% of US stocks.
  • EPZM's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
  • EPZM's current lowest rank is in the Quality metric (where it is better than 3.07% of US stocks).

EPZM Stock Summary

  • EPZM's price/sales ratio is 38.13; that's higher than the P/S ratio of 93.47% of US stocks.
  • With a year-over-year growth in debt of 233.6%, Epizyme Inc's debt growth rate surpasses 95.5% of about US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for EPZM comes in at -20.53% -- higher than that of only 12.62% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Epizyme Inc are GTYH, MTEM, AAOI, XENT, and TWOU.
  • Visit EPZM's SEC page to see the company's official filings. To visit the company's web site, go to www.epizyme.com.

EPZM Stock Price Chart Interactive Chart >

Price chart for EPZM

EPZM Price/Volume Stats

Current price $8.81 52-week high $22.00
Prev. close $8.53 52-week low $6.70
Day low $8.53 Volume 788,900
Day high $8.91 Avg. volume 1,054,616
50-day MA $8.31 Dividend yield N/A
200-day MA $10.73 Market Cap 898.41M

Epizyme, Inc. (EPZM) Company Bio


Epizyme, Inc. discovers and develops epigenetic therapies for cancer patients. The company was founded in 2007 and is based in Cambridge, Massachusetts.


EPZM Latest News Stream


Event/Time News Detail
Loading, please wait...

EPZM Latest Social Stream


Loading social stream, please wait...

View Full EPZM Social Stream

Latest EPZM News From Around the Web

Below are the latest news stories about Epizyme Inc that investors may wish to consider to help them evaluate EPZM as an investment opportunity.

Epizyme gains as peer Constellation attracts sizable premium from MorphoSys

Constellation Pharmaceuticals ([[CNST]] +67.2%) has risen more than two-thirds in value after agreeing to be acquired by German biotech MorphoSys AG (MOR) in a deal valued at $1.7B.The offer price of $34.00 per share in cash for Constellation’s common stock indicates a premium of ~70% to the five-day volume-weighted average share...

Seeking Alpha | June 2, 2021

Epizyme to Participate in Jefferies Virtual Healthcare Conference

Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that Robert Bazemore, President and Chief Executive Officer, will participate in a fireside chat during the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 2:30 p.m. ET.

Yahoo | May 25, 2021

Epizyme Announces Preclinical and Clinical Data to be Presented in Oral and Poster Sessions at Upcoming Medical Conferences in June

Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that new preclinical and clinical data will be presented at upcoming medical meetings in June.

Yahoo | May 12, 2021

2 “Strong Buy” Stocks Insiders Are Snapping Up

One strategy for selecting top stocks is to track insider transactions. After all, if insiders are dipping into their own pockets you can imagine it’s because they believe the stock looks compelling. A Harvard study revealed that insider purchases earn “abnormal” returns of more than 6% per year. The authors of the study conclude that insider buyers “have a good feel for near-term developments within their firm.” The advantage of following these insiders isn’t just that they are privy to data which the rest of us don’t necessarily know – it’s also that they are held responsible for their decisions.

Michael Marcus on TipRanks | April 1, 2021

The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 23) BioLife Solutions, Inc. (NASDAQ: BLFS ) ( announced a M&A transaction and quarterly results) Gain Therapeutics, Inc. (NASDAQ: GANX ) (IPOed Thursday) Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) Organogenesis Holdings Inc. (NASDAQ: ORGO ) Soliton, Inc. (NASDAQ: SOLY ) Radius Health, Inc. (NASDAQ: RDUS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 23) Adagene Inc. (NASDAQ: ADAG ) Bellerophon Therapeutics, Inc. (NASDAQ: BLPH ) Concert Pharmaceuticals, Inc. (NASDAQ: CNCE ) Connect Biopharma Holdings Limited (NASDAQ: CNTB ) (IPOed Friday) Epizyme, Inc. (EPZM) Finch Therapeutics Group, Inc. (NASDAQ: FNCH ) (IPOed Friday) Frequency...

Benzinga | March 24, 2021

Read More 'EPZM' Stories Here

EPZM Price Returns

1-mo -3.50%
3-mo -4.55%
6-mo -30.85%
1-year -54.52%
3-year -41.07%
5-year -25.28%
YTD -18.88%
2020 -55.85%
2019 299.35%
2018 -50.92%
2017 3.72%
2016 -24.47%

Continue Researching EPZM

Want to see what other sources are saying about Epizyme Inc's financials and stock price? Try the links below:

Epizyme Inc (EPZM) Stock Price | Nasdaq
Epizyme Inc (EPZM) Stock Quote, History and News - Yahoo Finance
Epizyme Inc (EPZM) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9631 seconds.